Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals

Nuclear Medicine and Biology

Volumn 30, Issue 7, 2003, Pages 725-731

  Mathias, Carla J ^a   Lewis, Michael R ^d   Reichert, David E ^d   Laforest, Richard ^d   Sharp, Terry L ^d   Lewis, Jason S ^d   Yang, Zhen Fan ^b   Waters, David J ^c   Snyder, Paul W ^c   Low, Philip S ^b   Welch, Michael J ^d   Green, Mark A ^a  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FOLATE RECEPTOR; GALLIUM DEFEROXAMINE FOLATE GA 66; GALLIUM DEFEROXAMINE FOLATE GA 68; RECEPTOR; TRACER; UNCLASSIFIED DRUG; CARRIER PROTEIN; CELL SURFACE RECEPTOR; DEFEROXAMINE; DEFEROXAMINE GAMMA FOLATE CONJUGATE; DEFEROXAMINE-GAMMA-FOLATE CONJUGATE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FOLATE BINDING PROTEIN; FOLATE-BINDING PROTEIN; FOLIC ACID; GALLIUM; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CELL STRAIN KB; CONJUGATE; CONTROLLED STUDY; CYCLOTRON; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG HALF LIFE; DRUG SCREENING; DRUG TARGETING; FEASIBILITY STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; PROTEIN TARGETING; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EVALUATION; ISOTOPE LABELING; METABOLISM; METHODOLOGY; NEOPLASM; SCINTISCANNING; SYNTHESIS; VALIDATION STUDY;

ANIMALS; AUTORADIOGRAPHY; CARRIER PROTEINS; DEFEROXAMINE; FEASIBILITY STUDIES; FLUORODEOXYGLUCOSE F18; FOLIC ACID; GALLIUM RADIOISOTOPES; HUMANS; ISOTOPE LABELING; KB CELLS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, CELL SURFACE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0141448741     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(03)00080-5     Document Type: Article

References (31)

1. Boerman O.C., van Niekerk C.C., Makkink K., Hanselaar T.G., Kenemans P., Poels L.G. Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens. Int J Gynecol Pathol. 10:1991;15-25.
2. Coney L.R., Tomassetti A., Carayannopoulos L., Frasca V., Kamen B.A., Colnaghi M.I., Zurawski V.R. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res. 51:1991;6125-6132.
3. Garin-Chesa P., Campbell I., Saigo P.E., Lewis J.L., Old L.J., Rettig W.J. Trophoblast and ovarian cancer antigen LK26 Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein . Am J Pathol. 142:1993;557-567.
4. 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging. J Nucl Med. 40:1999;1563-1569.
5. Holm J., Hansen S.I., Hoier-Madsen M., Bostad L. High-affinity folate binding in human choroids plexus. Biochem J. 280:1991;267-271.
6. Konda S.D., Aref M., Brechbiel M., Wiener E.C. Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor work in progress . Invest Radiol. 35:2000;50-57.
7. Konda S.D., Aref M., Wang S., Brechbiel M., Wiener E.C. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. MAGMA. 12:2001;104-113.
8. Leamon C.P., Low P.S. Cytotoxicity of momordin-folate conjugates in cultured human cells. J Biol Chem. 267:1992;24966-24971.
9. Leamon C.P., Pastan I., Low P.S. Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells Contribution of translocation domain . J Biol Chem. 268:1993;24847-24854.
10. Leamon C.P., Low P.S. Selective targeting of malignant cells with cytotoxin-folate conjugates. J Drug Target. 2:1994;101-112.
11. Lee R.J., Low P.S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta. 1233:1995;134-144.
12. Lewis M.R., Reichert D.E., Laforest R., Margenau W.H., Shefer R.E., Klinkowstein R.E., Hughey B.J., Welch M.J. Production and purification of gallium-66 for preparation of tumor-targeting radiopharmaceuticals. Nucl Med Biol. 29:2002;701-706.
13. Li S., Deshmukh H.M., Huang L. Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm Res. 15:1998;1540-1545.
14. Lu J.Y., Lowe D.A., Kennedy M.D., Low P.S. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. J Drug Target. 7:1999;43-53.
15. Mathias C.J., Wang S., Lee R.J., Waters D.J., Low P.S., Green M.A. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J Nucl Med. 37:1996;1003-1008.
16. 111In]In-DTPA-folate, a folate-receptor-targeted radiopharmaceutical. Nucl Med Biol. 25:1998;585-587.
17. Mathias C.J., Wang S., Waters D.K., Turek J.J., Low P.S., Green M.A. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J Nucl Med. 39:1998;1579-1585.
18. 67Ga-deferoxamine-folate to folate-receptor-positive human KB tumor xenografts. Nucl Med Biol. 26:1999;23-25.
19. Mattes M.J., Major P.P., Goldenberg D.M., Dion A.S., Hutter R.V., Klein K.M. Patterns of antigen distribution in human carcinomas. Cancer Res. 50:(suppl):1990;880S.
20. Ross J.F., Chaudhuri P.K., Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer. 73:1994;2432-2443.
21. Selhub J., Emmanouel D., Stavropoulos T., Arnold R. Renal folate absorption and the kidney folate binding protein. I. Urinary clearance studies. Am J Physiol. 252:1987;F750-756.
22. 111In-DTPA-Folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 2003;44:700-7.
23. Toffoli G., Cernigoi C., Russo A., Gallo A., Bagnoli M., Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 74:1997;193-198.
24. Toffoli G., Russo A., Gallo A., Cernigoi C., Miott S., Sorio R., Tumolo S., Boiocchi M. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer. 79:1998;121-126.
25. 67Ga-deferoxamine-folate, a potential radiopharmaceutical for tumor imaging. Bioconjugate Chem. 7:1996;56-62.
26. 111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjugate Chem. 8:1997;673-679.
27. Ward C.M., Acheson N., Seymour L.W. Folic acid targeting of protein conjugates into ascites tumour cells from ovarian cancer patients. J Drug Target. 8:2000;119-123.
28. Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawski V.R., Kamen B.A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52:1992;3396-3401.
29. Weitman S.D., Weinberg A.G., Coney L.R., Zurawski V.R., Jennings D.S., Kamen B.A. Cellular localization of the folate receptor potential role in drug toxicity and folate homeostasis . Cancer Res. 52:1992;6708-6711.
30. Weitman S.D., Frazier K.M., Kamen B.A. The folate receptor in central nervous system malignancies of childhood. J Neurol Oncol. 21:1994;107.
31. Williams W.M., Huang K.C. Renal tubular transport of folic acid and methotrexate in the monkey. Am J Physiol. 242:1982;F484-490.